Evidence Of Platelet Activation by Flowcytometry Following Hormone Replacement Therapy In Post Menopausal Women
Platelet activation is one of the underlying mechanisms causing thrombosis. However women are generally protected from thrombotic events before menopause. Previous study showed that there was an evidence of platelet activation in post menopausal women and it was related to the level of serum estr...
| Main Author: | |
|---|---|
| Format: | Monograph |
| Language: | English |
| Published: |
Universiti Sains Malaysia
2009
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/57370/1/PROF%20MADYA%20DR%20ROSLINE%20HASSAN.pdf |
| Summary: | Platelet activation is one of the underlying mechanisms
causing thrombosis. However women are generally protected from thrombotic events before menopause. Previous
study showed that there was an evidence of platelet activation in post menopausal women and it was related to the
level of serum estradiol yet remain questionable. Many
immunoassays by EI.ISA were used to measure platelet activation. Thus out aim was to study the platelet activation by
flow cytometry on post menopausal women receiving hormone replacement therapy.
Methodology: Total of 48 volunteers postmenopausal
women were recruited from gynaecology clinic. All women
were later given HRT (Primarine or Progestigen) for 2
weeks. 10 mls of blood pre and post HRT was collected in
3.2% sodium citrate bottle. Platelet activation was measured
by flow cytometric analysis using CD62P and PAC 1 FITC as
monoclonal markers.
Results: CD 62P and PAC1 FITC expression markers
in post treatment with HRT show dramatically decreased
compare to pre treatment level. CD62P were reduced significantly from 8.51 ± 12.56% to 3.15 ± 6.64% and PAC1
FITC from 41.75 ± 26.85% to 20.86 ± 19.02% after two
weeks treatment (p<0.05).
Conclusion: CD62P and PAC1 by flow cytometry are
both useful markers to measure platelet activation. Short term treatment with Primarine or combined HRT reduced
the circulating activated platelets as measured by flow
cytometry which indicates a reduced risk of thrombotic
event. Further study is required on its long term effect. |
|---|